



Book Now By:
 Registering Online: <http://www.bio2bevents.com/bio2b-registration/registration>
 By Phone: +44 (0)207 691 3568 By Email: info@bio2business.com

Biotech & Pharma Package
£250 + VAT
 Available to biotech and pharma delegates (non service providers only)

Package	Price	Features
CRO Sponsor Package	£1550 + VAT per delegate	Single delegate access to event and pre-event access to partnering software
Silver Sponsor Package	£1800 + VAT	Single delegate access to event and pre-event access to partnering software + Branding Package (see media pack for details)
Silver Sponsor Package	£2050 + VAT	X2 delegate access to event and pre-event access to partnering software + Branding Package (see media pack for details)
Banner Stand Exhibition Sponsor Package	£2500 + VAT	X2 delegate access to event and pre-event access to partnering software + Banner Stand + Branding Package (see media pack for full details)
Exhibition Sponsor Package	£2750+ VAT	X2 delegate access to event and pre-event access to partnering software + Stand (table top stand solution) + Branding Package (see media pack for details)
Exhibition Sponsor Package	£3000 + VAT	X3 delegate access to event and pre-event access to partnering software + Stand (table top stand solution) + Branding (see media pack for full details)
Gold Sponsor Package	£4500 + VAT	X3 delegate access to event and pre-event access to partnering software + 10 Minute Outsourcing Case Study Presentation + Stand (Table Top Stand Solution) + Branding (see media pack for full details)
Key Sponsor	Available on Request	Contact Bio2Business for a tailored package
Additional Delegate PAccess for CROs (only in addition to one of the package outlined above)	£390 + VAT	Includes full access to event and full access to pre-event partnering software
Sole Trader Consultant Rate (applicable to Sole Trader or Limited Company where proprietor consultant is the sole employee)	£390 + VAT	Includes full access to event and full access to pre-event partnering software

- Insight from expert speakers including:
- Dr Garry Pairaudeau**
Head of External Sciences, AstraZeneca
 - Dr Darcy Black**
Senior Director, External Innovation Lead, Grunenthal GmbH
 - Dr Stefan Jaroch**
Head of External Innovation Technology, Bayer Pharma
 - Dr Paul Quinn**
Director Clinical Operations, Vectura
 - Lidia Cappellina**
Head of Outsourcing Management, CHIESI FARMACEUTICI S.p.A.
 - Dr David Andrews**
Associate Director, Oncology Chemistry, AstraZeneca

22nd September, Royal College of Physicians, London, UK

Key CRO Sponsors

Gold Sponsors	Exhibition Sponsors	Silver Sponsors
 		 <p style="text-align: center;">Bioregion and Conference Partners</p> 

What You Can Expect From BOS 2015

- Update Technical Operations Skill Sets
- Build Specialist Outsourcing Knowledge
- Make Efficient Use Of Limited Travel Budgets By Meeting Your Suppliers All Under 1 Roof
- Refine Outsourcing Business Process
- Meet New CMO and CRO Partners
- Network with Peers from Biotech, Pharma and CMO/CRO Community
- Strengthen Existing CMO/ CRO Supplier Relationships
- A Friendly, Welcoming Event Which Fosters Networking & Partnering





PARTNERING

PRESENTATION

EXHIBITION

NETWORKING

Introduction to BOS 2015 and to the BOS Events Formula

Biotech Outsourcing Strategies (BOS) takes place on the 22nd of September at the Royal College of Physicians in London. Established in 2006, BOS is unique in offering 2 parallel tracks in discovery/early development outsourcing and clinical outsourcing. As an attendee at BOS 2015 you will learn new perspectives and approaches to tackling shared challenges in R&D outsourcing, delivered through our programme of speakers. You will touch base with your CRO and CMO network, facilitated by our 1 to 1 meeting planner software. Finally, you will be able to build new networks with partners in R&D outsourcing in a relaxed and friendly environment, tried and tested over 10 years of BOS Events.

Who should attend BOS 2015

From Biotech & Pharma: Executives involved in the following disciplines: Discovery biology, discovery chemistry, pharmacology, DMPK, lead validation, lead optimisation, in vitro ADME, early scale up, scale up, pre-formulation, formulation, CMC, regulatory affairs, clinical development, clinical operations, project managers, programme managers, clinical research, outsourcing managers, contracts managers.

From CROs and CMO – business development, sales, marketing and corporate management functions.

Featured speaker profiles



Garry Pairaudeau is currently Head of External Sciences at AstraZeneca with responsibility for Open Innovation, external collaborations in the chemistry and hit identification areas and

discovery chemistry outsourcing. He obtained his PhD in chemistry from the University of Southampton in 1991, followed by post-doctoral work at UC Irvine California. He joined AstraZeneca in 1994 as a medicinal chemist and was part of the medicinal chemistry team that discovered Brilinta. He has experience leading projects through all phases of Drug Discovery contributing to multiple clinical candidates in the respiratory inflammation and CV areas. He has a long standing interest in lead generation, hit identification and diversity screening. Prior to taking up his current position in 2012 he was Director of Chemistry for the cardiovascular group at Alderley Park.



Dr Stefan Jaroch
Head of External Innovation,
Bayer Pharma:

Stefan Jaroch studied chemistry at the University of Bonn and obtained his PhD from the Ludwig Maximilians-Universität, Munich, in 1993. After a postdoc at the University of California, Irvine, he joined Schering AG and worked as medicinal chemist from 1995-2000 in Berlin and from 2000-2001 at the US subsidiary Berlex Biosciences in Richmond, CA. From 2001-2007, he was director in the medicinal chemistry department in Berlin, and from 2007-2010 in the medicinal chemistry department of Bayer Schering Pharma in Wuppertal. In his 15 years of pharma research experience his main interests were in the areas of anti-inflammation and oncology research. He holds an honorary professorship at the chemistry department of the Philipps-Universität Marburg since 2008.

Since 2010, he focuses on collaborations with partners from academia, research institutes, pharmas, biotech, and CROs. As Head of External Innovation Technologies he is responsible for partnering activities referring to early drug discovery assets, technologies, and services, also including open innovation approaches.



Dr Phil Jones
Director, European Screening
Centre (Newhouse):

Phil received his PhD from the University of Manchester and studied at Imperial College with Professor S V Ley. In 1986 Phil joined Roche Discovery Welwyn, UK as a medicinal chemistry team leader, then project leader and departmental head. In 2001, Phil joined Organon and in 2003 became Executive Director with responsibility for the chemistry group at Newhouse, Scotland which became part of Schering-Plough Research Institute in 2007 and MSD in 2009. In 2010 and 2011 Phil was acting site head of the Newhouse facility managing the closure of the site and leading the successful search for a new owner. During 2012 Phil was a member of the consortium which was awarded funding for the IMI European Lead Factory and in 2013 he was appointed Director of the European Screening Centre at Newhouse. Phil was elected a Fellow of the Royal Society of Chemistry in 2005 and is an author on over 50 scientific papers and patents.



David Andrews
Associate Director Oncology
Chemistry, AstraZeneca:

Dr David Andrews, (BPharm, PhD, GPhC, MRPharmS, FRSC) trained as a pharmacist at Nottingham University and then undertook PhD research in organic synthesis at Liverpool University. From 1990-2003, he held positions of increasing seniority in medicinal chemistry at GlaxoSmithKline. Since 2003, he has worked as an Associate Director in the Oncology iMed Chemistry Department of AstraZeneca where he led projects delivering the development candidates AZD4547 and AZD9496. He currently heads AstraZeneca's Oncology early-stage chemistry collaboration and Open Innovation efforts alongside a secondment as an Industry Associate at the RSC, leading the National Compound Collection Open Innovation initiative.



Liz Eagling-Vose
Associate Director, Clinical Studies,
Vectura:

Liz Eagling-Vose has 12 years pharmaceutical industry experience, with a strong background in Clinical Operations, currently Associate Director - clinical studies, at Vectura an SME pharmaceutical company specialising in inhaled therapies. Worked within both CRO and Pharma industry, including AstraZeneca, and Parexel. Clinical experience includes study management, site monitoring/management, medical writing, data management, ethics and regulatory applications. BSc (Hons) biology with analytical science, presently studying for MBA.



Paul Quinn
Director Clinical Operations,
Vectura:

Paul Quinn has 20 years Clinical Development experience with a recent focus on Clinical Operations, currently Director – Clinical Operations, at Vectura an SME pharmaceutical company specialising in inhaled therapies. Paul has worked in the Pharma industry previously at Pfizer and Shire where he lead new initiatives in electronic capture of patient data and more recently novel approaches in patient recruitment in and engagement with clinical trials, these included eConsents and trial websites. Paul has also lead effective changes in clinical outsourcing strategy at Shire and Vectura.

Here are some comments from past attendees...

Good size meeting with a good mixture of presentations and opportunities to meet customers and vendors."

Following BOS 2014, 23rd September, 2014

Dr Rudolf Hausmann, VP Technical Development & Operations, Santhera Pharma Ltd.

BOS 2015, 22nd September, 2015 Discovery/Early Development Track

BOS 2015, 22nd September, 2015 Clinical Operations Track

08.00
Registration and Partnering

Outsourcing & Discovery Module

Chair: Brian Cox, Professor of Pharmaceutical Chemistry, University of Sussex

10.00 Key components in successful Discovery Outsourcing.

Dr Garry Pairaudeau, Head of External Sciences, AstraZeneca.

10.30 European Lead Factory – Creating New Opportunities for Drug Discovery.

Stuart McElroy, Head of Biology, European Screening Centre, Newhouse.

11.00 Drug discovery collaborations at Bayer HealthCare – expectations and experiences.

Dr Stefan Jaroch, Global Drug Discovery, External Innovation Technologies, Bayer Pharma AG.

11.30 Managing external partnerships to drive internal innovation.

Dr Janet Fernihough, Director, Insipoda Ltd.

12.00 Lunch and partnering.

Outsourcing Early Development Module

Chair: Miriam McCloskey, External Sourcing Consultant, Perceptive Partnering.

13.30 Unlocking value in outsourcing partnerships – Exploring Grunenthal's innovative approach to collaborative R&D.

Dr Darcey Black, Senior Director, External Innovation Lead, Grunenthal.

14.00 Effective quality management - strategies, organisation and systems required for outsourced pharmaceutical development.

Dr Peter Murray, Consultant and Former Quality Director.

14.30 Building a CMC package to meet regulatory requirements at IMPD - key learnings when interacting with regulatory agencies.

Dr Richard Dennett, Director, Voisin Consulting Life Science.

15.00 Aligning custom research and development organisations to the needs of biotech and pharma.

Christian Jones, Commercial Director, Johnson Matthey

15.30 Planning ahead.... - formulation development and scale-up.

Doreen Coull, Regional Sales Director, Albany Molecular Research Inc.

15.30 Refreshments and partnering.

Clinical Operations Outsourcing

Chair: Sandra Johnson, Director Outsourcing & Relationship Management, Medicines for Malaria Venture

10.00 Integrating supplier performance management in to a total Quality Management Process.

Lidia Cappellina, Head of Outsourcing Management, CHIESI FARMACEUTICI S.p.A.

10.30 Utilising Agile Project Management theory in outsourced clinical research.

Roger Joby, Managing Director, 1to1to1 Ltd.

11.00 Expediting Clinical Research in the UK - Case Studies from the NIHR Clinical Research Network.

Matt Cooper, Business Development & Marketing Director, NIHR Clinical Research Network.

11.30 Clinical case studies: "The good, the bad, and the ugly".

Ronald Openshaw, CEO, Simbec Orion.

12.00 Lunch and partnering

Clinical Operations Outsourcing

Chair: Dr Stephen Greentree, Director of Clinical Science, Takeda Pharma Europe

13.30 Regulatory developments to support clinic innovation in Europe.

Dr Kirsty Wydenbach, Medical Assessor, Clinical Trials Unit, MHRA.

14.00 The rise of a resurgent industry.

Dr Mohammad Charki, Partnerships Director, Open Innovation Strategy, Scouting & Partnerships, Sanofi.

14.30 Exploring the benefits of outsourcing to niche, specialist, clinical CROs v's the full service approach.

Dr Paul Quinn, Director of Clinical Operation & Liz Eagling-Vose, Associate Director, Clinical Studies, Vectura.

15.00 Why most CRO partnerships don't deliver - and what you can do to make sure yours does.

John Faulkes, Consultant, PPMLD & David Davies, Managing Director, David Davies Pharma Consulting.

15.30 Refreshments and partnering

16.00 Interactive Plenary.

Open Innovation role in Drug Discovery & Early Development. This session will explore how the landscape continues to evolve; who are the key players, what different collaborative models are being explored across the spectrum. Aim: for you to understand what may benefit your program and or business.

Chair: Duncan Judd, CEO, Awridian Ltd.

Panel Member: **Compound passport.**

Dr David Andrews, Associate Director, Oncology Chemistry, AstraZeneca.

Panel Member: **Drug discovery grant applications: success through collaboration.**

Dr David Clark, Director CADD & Information Services, Argenta Discovery.

Panel Member: **An open innovation approach to neuroscience target validation.**

Dr Peter Atkinson, Senior Manager – Open Innovation, EISAI Ltd.

Panel Member: **The Francis Crick Institute – discovery without boundaries.**

Dr Chris Watkins, Head of Knowledge Exchange, The Francis Crick Institute.

17.00 Conference Close – Drinks Reception.

"For those involved with outsourcing, either as a customer or as a supplier, I can recommend this as one of the truly focused events to explore and find new partners."

Following BOS 2014, 23rd September, 2014

Dr Hans Lindner, Head of Global Pharma Development, Bayer Schering Pharma AG (BOS cmc 16th June 2011)

"BOS 2014 is always a pleasure to attend. It is well organized, the talks are usually of high quality and the number of suppliers is suitable for an event of this size. I can only recommend attending BOS."

Following BOS 2014, 23rd September, 2014

Dr Frederik Barfoed Beck, CMC outsourcing Manager Zealand Pharma A/S